VircapSeq Virus Detection in Sézary Syndrome
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02836886 |
Recruitment Status :
Completed
First Posted : July 19, 2016
Last Update Posted : February 8, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Lymphoma, T-Cell, Cutaneous Sézary Syndrome |
Study Type : | Observational |
Actual Enrollment : | 6 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Searching for Oncogenic Viruses in Sézary Cells Using a Novel Viral Discovery Technique, VirCapSeq-VERT |
Study Start Date : | June 2016 |
Actual Primary Completion Date : | October 2016 |
Actual Study Completion Date : | October 2016 |

Group/Cohort |
---|
Sézary syndrome
Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
|
- Prevalence of viral sequences present in malignant T cells of patients with Sézary syndrome [ Time Frame: Up to 1 week ]White blood cells samples will be analyzed with technique called "VirCapSeq-VERT"
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients with Sézary syndrome diagnosed according to the WHO-EORTC classification.
Exclusion Criteria:
- Pregnant patients.
- Patients with known anemia with documented <7.5 mg/dL.
- Patients who are unable to give informed consent.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02836886
United States, New York | |
Columbia University Medical Center | |
New York, New York, United States, 10032 |
Principal Investigator: | Larisa G Geskin, MD | Columbia University |
Responsible Party: | Larisa Geskin, Associate Professor of Dermatology in Medicine at the Columbia U, Department of Dermatology, Columbia University |
ClinicalTrials.gov Identifier: | NCT02836886 |
Other Study ID Numbers: |
AAAQ9017 |
First Posted: | July 19, 2016 Key Record Dates |
Last Update Posted: | February 8, 2017 |
Last Verified: | February 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Sezary Syndrome Lymphoma, T-Cell Lymphoma, T-Cell, Cutaneous Syndrome Disease Pathologic Processes Lymphoma, Non-Hodgkin |
Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |